These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17228128)

  • 1. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor: a promising target in solid tumours.
    Laskin JJ; Sandler AB
    Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
    Ang KK; Andratschke NH; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced or metastatic pancreatic cancer: molecular targeted therapies.
    Bayraktar S; Rocha-Lima CM
    Mt Sinai J Med; 2010; 77(6):606-19. PubMed ID: 21105124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for pancreatic cancer.
    Wolff RA
    Cancer J; 2001; 7(4):349-58. PubMed ID: 11561610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
    Arnold D; Peinert S; Voigt W; Schmoll HJ
    Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future strategies for targeted therapies and tailored patient management in pancreatic cancer.
    Ko AH
    Semin Oncol; 2007 Aug; 34(4):354-64. PubMed ID: 17674964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer: from molecular signature to target therapy.
    Longo R; Cacciamani F; Naso G; Gasparini G
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):197-211. PubMed ID: 18436450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
    Wheatley-Price P; Shepherd FA
    Curr Opin Oncol; 2008 Mar; 20(2):162-75. PubMed ID: 18300766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
    Chang BW; Saif MW
    JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Andersson M; Kamby C
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.
    Viloria-Petit AM; Kerbel RS
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):914-26. PubMed ID: 14967451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeting therapy for pancreatic cancer.
    Xiong HQ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S69-77. PubMed ID: 15316751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.
    Macarulla T; Casado E; Ramos FJ; Valverde C; Tabernero J
    Onkologie; 2006 Mar; 29(3):99-105. PubMed ID: 16514271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.